Atorvastatin Calcium Market By Form (Tablets, Others) , By Application (Hypercholesterolemia, Hyperlipidemia, Others) By Distribution channel (Hospital pharmacies, Drug store & retail pharmacies, Online providers.) : Global Opportunity Analysis and Industry Forecast, 2024-2033
The atorvastatin calcium market was valued at $298.3 million in 2023, and is projected t%li%reach $487.8 million by 2033, growing at a CAGR of 5% from 2024 t%li%2033.
Atorvastatin calcium is a statin medication, which acts as the first line of treatment for the prevention of cardiovascular diseases. It lowers the cholesterol levels in the blood by inhibiting the enzyme HMG-CoA reductase, which plays a crucial role in cholesterol synthesis in the liver. This medication is effective in lowering low-density lipoprotein (LDL) cholesterol, and can als%li%help t%li%raise high-density lipoprotein (HDL) cholesterol. By managing cholesterol levels, atorvastatin calcium plays a crucial role in preventing heart attacks, strokes, and other serious cardiovascular events.
The growth of the global atorvastatin calcium market is majorly driven by alarming increase in prevalence of cardiovascular diseases. According t%li%the World Heart Federation, cardiovascular diseases are the leading cause of death worldwide as compared t%li%any other cause. Approximately 20.5 million deaths were reported in 2021 across the globe. In addition, surge in geriatric population significantly contributes toward the market growth. This is attributed t%li%the fact that aged individuals are highly susceptible t%li%hypercholesterolemia and related cardiovascular conditions, which, in turn, leads t%li%higher demand for cholesterol-lowering medications like atorvastatin, thereby boosting the market growth. As per AHA 2019 Heart Disease and Stroke Statistical Update, the incidence of cardiovascular diseases was reported t%li%be 77.2% in males and 78.2% in females, from ages 60–79 years. Moreover, rise in sedentary lifestyles and unhealthy eating patterns are leading t%li%higher cholesterol levels among the population, thereby increasing the need for atorvastatin calcium. Furthermore, rise in public awareness of the importance of managing cholesterol levels for overall health and availability of generic versions of atorvastatin calcium boost the growth of the global market. Increase in popularity of combination therapies acts a key trend that is expected t%li%augment the market growth. For instance, the use of atorvastatin calcium in combination with other drugs, such as ezetimibe, is becoming more common t%li%enhance therapeutic outcomes for managing cholesterol levels. However, rise in concerns about potential side effects of atorvastatin calcium such as muscle pain, liver damage, and interactions with other medications can limit its use, which hampers the market growth. In addition, availability of alternative statins and other cholesterol-lowering drugs acts as key deterrent factor of the global market. On the contrary, innovations in drug formulation and delivery systems are enhancing the efficacy and convenience of atorvastatin calcium, which are expected t%li%offer lucrative opportunities for the market growth during the forecast period.
The global atorvastatin calcium market is segmented int%li%form, application, distribution channel, and region. On the basis of form, the market is categorized int%li%tablets and others. By application, it is divided int%li%hypercholesterolemia, hyperlipidemia, and others. Depending on distribution channel, it is categorized int%li%hospital pharmacies, drug store & retail pharmacies, and online providers. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of form, the tablets segment dominated the market in 2023, and is is expected t%li%dominate from 2024 t%li%2033.
By application, hypercholesterolemia is anticipated t%li%be the lucrative segment in the global atorvastatin calcium market in the coming years.
Depending on distribution channel, online pharmacies is projected t%li%emerge as the leading segment by 2033.
Region wise, North America held the largest market share in terms of revenue in 2023, and is expected t%li%dominate the atorvastatin calcium market during the forecast period.
Competition Analysis
Competitive analysis and profiles of the major players in the global atorvastatin calcium market include Mylan Pharmaceuticals Inc., Novartis AG, GlaxoSmithKline plc, Amgen Inc., Sanofi SA, Teva Pharmaceuticals Industries Ltd, Merck and Co. Inc., Bristol-Myers Squibb Company, AstraZeneca Plc., and Pfizer Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships t%li%sustain the intense competition and gain a strong foothold in the global market.
Additional benefits you will get with this purchase are:
By Form
Atorvastatin calcium is a statin medication, which acts as the first line of treatment for the prevention of cardiovascular diseases. It lowers the cholesterol levels in the blood by inhibiting the enzyme HMG-CoA reductase, which plays a crucial role in cholesterol synthesis in the liver. This medication is effective in lowering low-density lipoprotein (LDL) cholesterol, and can als%li%help t%li%raise high-density lipoprotein (HDL) cholesterol. By managing cholesterol levels, atorvastatin calcium plays a crucial role in preventing heart attacks, strokes, and other serious cardiovascular events.
The growth of the global atorvastatin calcium market is majorly driven by alarming increase in prevalence of cardiovascular diseases. According t%li%the World Heart Federation, cardiovascular diseases are the leading cause of death worldwide as compared t%li%any other cause. Approximately 20.5 million deaths were reported in 2021 across the globe. In addition, surge in geriatric population significantly contributes toward the market growth. This is attributed t%li%the fact that aged individuals are highly susceptible t%li%hypercholesterolemia and related cardiovascular conditions, which, in turn, leads t%li%higher demand for cholesterol-lowering medications like atorvastatin, thereby boosting the market growth. As per AHA 2019 Heart Disease and Stroke Statistical Update, the incidence of cardiovascular diseases was reported t%li%be 77.2% in males and 78.2% in females, from ages 60–79 years. Moreover, rise in sedentary lifestyles and unhealthy eating patterns are leading t%li%higher cholesterol levels among the population, thereby increasing the need for atorvastatin calcium. Furthermore, rise in public awareness of the importance of managing cholesterol levels for overall health and availability of generic versions of atorvastatin calcium boost the growth of the global market. Increase in popularity of combination therapies acts a key trend that is expected t%li%augment the market growth. For instance, the use of atorvastatin calcium in combination with other drugs, such as ezetimibe, is becoming more common t%li%enhance therapeutic outcomes for managing cholesterol levels. However, rise in concerns about potential side effects of atorvastatin calcium such as muscle pain, liver damage, and interactions with other medications can limit its use, which hampers the market growth. In addition, availability of alternative statins and other cholesterol-lowering drugs acts as key deterrent factor of the global market. On the contrary, innovations in drug formulation and delivery systems are enhancing the efficacy and convenience of atorvastatin calcium, which are expected t%li%offer lucrative opportunities for the market growth during the forecast period.
The global atorvastatin calcium market is segmented int%li%form, application, distribution channel, and region. On the basis of form, the market is categorized int%li%tablets and others. By application, it is divided int%li%hypercholesterolemia, hyperlipidemia, and others. Depending on distribution channel, it is categorized int%li%hospital pharmacies, drug store & retail pharmacies, and online providers. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of form, the tablets segment dominated the market in 2023, and is is expected t%li%dominate from 2024 t%li%2033.
By application, hypercholesterolemia is anticipated t%li%be the lucrative segment in the global atorvastatin calcium market in the coming years.
Depending on distribution channel, online pharmacies is projected t%li%emerge as the leading segment by 2033.
Region wise, North America held the largest market share in terms of revenue in 2023, and is expected t%li%dominate the atorvastatin calcium market during the forecast period.
Competition Analysis
Competitive analysis and profiles of the major players in the global atorvastatin calcium market include Mylan Pharmaceuticals Inc., Novartis AG, GlaxoSmithKline plc, Amgen Inc., Sanofi SA, Teva Pharmaceuticals Industries Ltd, Merck and Co. Inc., Bristol-Myers Squibb Company, AstraZeneca Plc., and Pfizer Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships t%li%sustain the intense competition and gain a strong foothold in the global market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting t%li%16 analyst hours t%li%solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent t%li%3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
- Patient/epidemiology data at country, region, global level
- Additional company profiles with specific t%li%client's interest
- Expanded list for Company Profiles
- Historic market data
- SWOT Analysis
By Form
- Tablets
- Others
- Hypercholesterolemia
- Hyperlipidemia
- Others
- Hospital pharmacies
- Drug store retail pharmacies
- Online providers.
- North America
- U.S.
- Canada
- Mexico
- Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
- Key Market Players
- Mylan Pharmaceuticals Inc.
- Novartis AG
- GlaxoSmithKline plc
- Amgen Inc.
- Sanofi SA
- Teva Pharmaceuticals Industries Ltd
- Merck and Co. Inc.
- Bristol-Myers Squibb Company
- AstraZeneca Plc
- Pfizer Inc.
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: AUTOIMMUNE DISEASE TESTING MARKET, BY PRODUCT TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Product Type
4.2. Instruments
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Consumables And Kits
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
CHAPTER 5: AUTOIMMUNE DISEASE TESTING MARKET, BY DISEASE TYPE
5.1. Market Overview
5.1.1 Market Size and Forecast, By Disease Type
5.2. Rheumatoid Arthritis
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Systemic Lupus Erythematous
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Scleroderma
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
5.5. Vasculitis
5.5.1. Key Market Trends, Growth Factors and Opportunities
5.5.2. Market Size and Forecast, By Region
5.5.3. Market Share Analysis, By Country
5.6. Inflammatory Bowel Disease
5.6.1. Key Market Trends, Growth Factors and Opportunities
5.6.2. Market Size and Forecast, By Region
5.6.3. Market Share Analysis, By Country
5.7. Others
5.7.1. Key Market Trends, Growth Factors and Opportunities
5.7.2. Market Size and Forecast, By Region
5.7.3. Market Share Analysis, By Country
CHAPTER 6: AUTOIMMUNE DISEASE TESTING MARKET, BY TEST TYPE
6.1. Market Overview
6.1.1 Market Size and Forecast, By Test Type
6.2. Antibodies And Immunolgic Test
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Inflammatory Markers
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
6.4. Routine Laboratory Tests
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, By Region
6.4.3. Market Share Analysis, By Country
6.5. Anti-Thyroglobulin Antibody
6.5.1. Key Market Trends, Growth Factors and Opportunities
6.5.2. Market Size and Forecast, By Region
6.5.3. Market Share Analysis, By Country
6.6. Others
6.6.1. Key Market Trends, Growth Factors and Opportunities
6.6.2. Market Size and Forecast, By Region
6.6.3. Market Share Analysis, By Country
CHAPTER 7: AUTOIMMUNE DISEASE TESTING MARKET, BY END USER
7.1. Market Overview
7.1.1 Market Size and Forecast, By End User
7.2. Hospitals And Clinics
7.2.1. Key Market Trends, Growth Factors and Opportunities
7.2.2. Market Size and Forecast, By Region
7.2.3. Market Share Analysis, By Country
7.3. Clinical Laboratories
7.3.1. Key Market Trends, Growth Factors and Opportunities
7.3.2. Market Size and Forecast, By Region
7.3.3. Market Share Analysis, By Country
7.4. Others
7.4.1. Key Market Trends, Growth Factors and Opportunities
7.4.2. Market Size and Forecast, By Region
7.4.3. Market Share Analysis, By Country
CHAPTER 8: AUTOIMMUNE DISEASE TESTING MARKET, BY REGION
8.1. Market Overview
8.1.1 Market Size and Forecast, By Region
8.2. North America
8.2.1. Key Market Trends and Opportunities
8.2.2. Market Size and Forecast, By Product Type
8.2.3. Market Size and Forecast, By Disease Type
8.2.4. Market Size and Forecast, By Test Type
8.2.5. Market Size and Forecast, By End User
8.2.6. Market Size and Forecast, By Country
8.2.7. U.S. Autoimmune Disease Testing Market
8.2.7.1. Market Size and Forecast, By Product Type
8.2.7.2. Market Size and Forecast, By Disease Type
8.2.7.3. Market Size and Forecast, By Test Type
8.2.7.4. Market Size and Forecast, By End User
8.2.8. Canada Autoimmune Disease Testing Market
8.2.8.1. Market Size and Forecast, By Product Type
8.2.8.2. Market Size and Forecast, By Disease Type
8.2.8.3. Market Size and Forecast, By Test Type
8.2.8.4. Market Size and Forecast, By End User
8.2.9. Mexico Autoimmune Disease Testing Market
8.2.9.1. Market Size and Forecast, By Product Type
8.2.9.2. Market Size and Forecast, By Disease Type
8.2.9.3. Market Size and Forecast, By Test Type
8.2.9.4. Market Size and Forecast, By End User
8.3. Europe
8.3.1. Key Market Trends and Opportunities
8.3.2. Market Size and Forecast, By Product Type
8.3.3. Market Size and Forecast, By Disease Type
8.3.4. Market Size and Forecast, By Test Type
8.3.5. Market Size and Forecast, By End User
8.3.6. Market Size and Forecast, By Country
8.3.7. Germany Autoimmune Disease Testing Market
8.3.7.1. Market Size and Forecast, By Product Type
8.3.7.2. Market Size and Forecast, By Disease Type
8.3.7.3. Market Size and Forecast, By Test Type
8.3.7.4. Market Size and Forecast, By End User
8.3.8. France Autoimmune Disease Testing Market
8.3.8.1. Market Size and Forecast, By Product Type
8.3.8.2. Market Size and Forecast, By Disease Type
8.3.8.3. Market Size and Forecast, By Test Type
8.3.8.4. Market Size and Forecast, By End User
8.3.9. UK Autoimmune Disease Testing Market
8.3.9.1. Market Size and Forecast, By Product Type
8.3.9.2. Market Size and Forecast, By Disease Type
8.3.9.3. Market Size and Forecast, By Test Type
8.3.9.4. Market Size and Forecast, By End User
8.3.10. Italy Autoimmune Disease Testing Market
8.3.10.1. Market Size and Forecast, By Product Type
8.3.10.2. Market Size and Forecast, By Disease Type
8.3.10.3. Market Size and Forecast, By Test Type
8.3.10.4. Market Size and Forecast, By End User
8.3.11. Spain Autoimmune Disease Testing Market
8.3.11.1. Market Size and Forecast, By Product Type
8.3.11.2. Market Size and Forecast, By Disease Type
8.3.11.3. Market Size and Forecast, By Test Type
8.3.11.4. Market Size and Forecast, By End User
8.3.12. Rest of Europe Autoimmune Disease Testing Market
8.3.12.1. Market Size and Forecast, By Product Type
8.3.12.2. Market Size and Forecast, By Disease Type
8.3.12.3. Market Size and Forecast, By Test Type
8.3.12.4. Market Size and Forecast, By End User
8.4. Asia-Pacific
8.4.1. Key Market Trends and Opportunities
8.4.2. Market Size and Forecast, By Product Type
8.4.3. Market Size and Forecast, By Disease Type
8.4.4. Market Size and Forecast, By Test Type
8.4.5. Market Size and Forecast, By End User
8.4.6. Market Size and Forecast, By Country
8.4.7. Japan Autoimmune Disease Testing Market
8.4.7.1. Market Size and Forecast, By Product Type
8.4.7.2. Market Size and Forecast, By Disease Type
8.4.7.3. Market Size and Forecast, By Test Type
8.4.7.4. Market Size and Forecast, By End User
8.4.8. China Autoimmune Disease Testing Market
8.4.8.1. Market Size and Forecast, By Product Type
8.4.8.2. Market Size and Forecast, By Disease Type
8.4.8.3. Market Size and Forecast, By Test Type
8.4.8.4. Market Size and Forecast, By End User
8.4.9. India Autoimmune Disease Testing Market
8.4.9.1. Market Size and Forecast, By Product Type
8.4.9.2. Market Size and Forecast, By Disease Type
8.4.9.3. Market Size and Forecast, By Test Type
8.4.9.4. Market Size and Forecast, By End User
8.4.10. Australia Autoimmune Disease Testing Market
8.4.10.1. Market Size and Forecast, By Product Type
8.4.10.2. Market Size and Forecast, By Disease Type
8.4.10.3. Market Size and Forecast, By Test Type
8.4.10.4. Market Size and Forecast, By End User
8.4.11. South Korea Autoimmune Disease Testing Market
8.4.11.1. Market Size and Forecast, By Product Type
8.4.11.2. Market Size and Forecast, By Disease Type
8.4.11.3. Market Size and Forecast, By Test Type
8.4.11.4. Market Size and Forecast, By End User
8.4.12. Rest of Asia-Pacific Autoimmune Disease Testing Market
8.4.12.1. Market Size and Forecast, By Product Type
8.4.12.2. Market Size and Forecast, By Disease Type
8.4.12.3. Market Size and Forecast, By Test Type
8.4.12.4. Market Size and Forecast, By End User
8.5. LAMEA
8.5.1. Key Market Trends and Opportunities
8.5.2. Market Size and Forecast, By Product Type
8.5.3. Market Size and Forecast, By Disease Type
8.5.4. Market Size and Forecast, By Test Type
8.5.5. Market Size and Forecast, By End User
8.5.6. Market Size and Forecast, By Country
8.5.7. Brazil Autoimmune Disease Testing Market
8.5.7.1. Market Size and Forecast, By Product Type
8.5.7.2. Market Size and Forecast, By Disease Type
8.5.7.3. Market Size and Forecast, By Test Type
8.5.7.4. Market Size and Forecast, By End User
8.5.8. Saudi Arabia Autoimmune Disease Testing Market
8.5.8.1. Market Size and Forecast, By Product Type
8.5.8.2. Market Size and Forecast, By Disease Type
8.5.8.3. Market Size and Forecast, By Test Type
8.5.8.4. Market Size and Forecast, By End User
8.5.9. South Africa Autoimmune Disease Testing Market
8.5.9.1. Market Size and Forecast, By Product Type
8.5.9.2. Market Size and Forecast, By Disease Type
8.5.9.3. Market Size and Forecast, By Test Type
8.5.9.4. Market Size and Forecast, By End User
8.5.10. Rest of LAMEA Autoimmune Disease Testing Market
8.5.10.1. Market Size and Forecast, By Product Type
8.5.10.2. Market Size and Forecast, By Disease Type
8.5.10.3. Market Size and Forecast, By Test Type
8.5.10.4. Market Size and Forecast, By End User
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top Winning Strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top Player Positioning, 2023
CHAPTER 10: COMPANY PROFILES
10.1. F. Hoffmann-La Roche Ltd
10.1.1. Company Overview
10.1.2. Key Executives
10.1.3. Company Snapshot
10.1.4. Operating Business Segments
10.1.5. Product Portfolio
10.1.6. Business Performance
10.1.7. Key Strategic Moves and Developments
10.2. Siemens
10.2.1. Company Overview
10.2.2. Key Executives
10.2.3. Company Snapshot
10.2.4. Operating Business Segments
10.2.5. Product Portfolio
10.2.6. Business Performance
10.2.7. Key Strategic Moves and Developments
10.3. Thermo Fisher Scientific Inc.
10.3.1. Company Overview
10.3.2. Key Executives
10.3.3. Company Snapshot
10.3.4. Operating Business Segments
10.3.5. Product Portfolio
10.3.6. Business Performance
10.3.7. Key Strategic Moves and Developments
10.4. Quest Diagnostics
10.4.1. Company Overview
10.4.2. Key Executives
10.4.3. Company Snapshot
10.4.4. Operating Business Segments
10.4.5. Product Portfolio
10.4.6. Business Performance
10.4.7. Key Strategic Moves and Developments
10.5. Abbott
10.5.1. Company Overview
10.5.2. Key Executives
10.5.3. Company Snapshot
10.5.4. Operating Business Segments
10.5.5. Product Portfolio
10.5.6. Business Performance
10.5.7. Key Strategic Moves and Developments
10.6. Werfen, S.A.
10.6.1. Company Overview
10.6.2. Key Executives
10.6.3. Company Snapshot
10.6.4. Operating Business Segments
10.6.5. Product Portfolio
10.6.6. Business Performance
10.6.7. Key Strategic Moves and Developments
10.7. Trinity Biotech
10.7.1. Company Overview
10.7.2. Key Executives
10.7.3. Company Snapshot
10.7.4. Operating Business Segments
10.7.5. Product Portfolio
10.7.6. Business Performance
10.7.7. Key Strategic Moves and Developments
10.8. Bio-Rad Laboratories, Inc.
10.8.1. Company Overview
10.8.2. Key Executives
10.8.3. Company Snapshot
10.8.4. Operating Business Segments
10.8.5. Product Portfolio
10.8.6. Business Performance
10.8.7. Key Strategic Moves and Developments
10.9. Grifols, S.A.
10.9.1. Company Overview
10.9.2. Key Executives
10.9.3. Company Snapshot
10.9.4. Operating Business Segments
10.9.5. Product Portfolio
10.9.6. Business Performance
10.9.7. Key Strategic Moves and Developments
10.10. Exagen Inc.
10.10.1. Company Overview
10.10.2. Key Executives
10.10.3. Company Snapshot
10.10.4. Operating Business Segments
10.10.5. Product Portfolio
10.10.6. Business Performance
10.10.7. Key Strategic Moves and Developments
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: AUTOIMMUNE DISEASE TESTING MARKET, BY PRODUCT TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Product Type
4.2. Instruments
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Consumables And Kits
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
CHAPTER 5: AUTOIMMUNE DISEASE TESTING MARKET, BY DISEASE TYPE
5.1. Market Overview
5.1.1 Market Size and Forecast, By Disease Type
5.2. Rheumatoid Arthritis
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Systemic Lupus Erythematous
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Scleroderma
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
5.5. Vasculitis
5.5.1. Key Market Trends, Growth Factors and Opportunities
5.5.2. Market Size and Forecast, By Region
5.5.3. Market Share Analysis, By Country
5.6. Inflammatory Bowel Disease
5.6.1. Key Market Trends, Growth Factors and Opportunities
5.6.2. Market Size and Forecast, By Region
5.6.3. Market Share Analysis, By Country
5.7. Others
5.7.1. Key Market Trends, Growth Factors and Opportunities
5.7.2. Market Size and Forecast, By Region
5.7.3. Market Share Analysis, By Country
CHAPTER 6: AUTOIMMUNE DISEASE TESTING MARKET, BY TEST TYPE
6.1. Market Overview
6.1.1 Market Size and Forecast, By Test Type
6.2. Antibodies And Immunolgic Test
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Inflammatory Markers
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
6.4. Routine Laboratory Tests
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, By Region
6.4.3. Market Share Analysis, By Country
6.5. Anti-Thyroglobulin Antibody
6.5.1. Key Market Trends, Growth Factors and Opportunities
6.5.2. Market Size and Forecast, By Region
6.5.3. Market Share Analysis, By Country
6.6. Others
6.6.1. Key Market Trends, Growth Factors and Opportunities
6.6.2. Market Size and Forecast, By Region
6.6.3. Market Share Analysis, By Country
CHAPTER 7: AUTOIMMUNE DISEASE TESTING MARKET, BY END USER
7.1. Market Overview
7.1.1 Market Size and Forecast, By End User
7.2. Hospitals And Clinics
7.2.1. Key Market Trends, Growth Factors and Opportunities
7.2.2. Market Size and Forecast, By Region
7.2.3. Market Share Analysis, By Country
7.3. Clinical Laboratories
7.3.1. Key Market Trends, Growth Factors and Opportunities
7.3.2. Market Size and Forecast, By Region
7.3.3. Market Share Analysis, By Country
7.4. Others
7.4.1. Key Market Trends, Growth Factors and Opportunities
7.4.2. Market Size and Forecast, By Region
7.4.3. Market Share Analysis, By Country
CHAPTER 8: AUTOIMMUNE DISEASE TESTING MARKET, BY REGION
8.1. Market Overview
8.1.1 Market Size and Forecast, By Region
8.2. North America
8.2.1. Key Market Trends and Opportunities
8.2.2. Market Size and Forecast, By Product Type
8.2.3. Market Size and Forecast, By Disease Type
8.2.4. Market Size and Forecast, By Test Type
8.2.5. Market Size and Forecast, By End User
8.2.6. Market Size and Forecast, By Country
8.2.7. U.S. Autoimmune Disease Testing Market
8.2.7.1. Market Size and Forecast, By Product Type
8.2.7.2. Market Size and Forecast, By Disease Type
8.2.7.3. Market Size and Forecast, By Test Type
8.2.7.4. Market Size and Forecast, By End User
8.2.8. Canada Autoimmune Disease Testing Market
8.2.8.1. Market Size and Forecast, By Product Type
8.2.8.2. Market Size and Forecast, By Disease Type
8.2.8.3. Market Size and Forecast, By Test Type
8.2.8.4. Market Size and Forecast, By End User
8.2.9. Mexico Autoimmune Disease Testing Market
8.2.9.1. Market Size and Forecast, By Product Type
8.2.9.2. Market Size and Forecast, By Disease Type
8.2.9.3. Market Size and Forecast, By Test Type
8.2.9.4. Market Size and Forecast, By End User
8.3. Europe
8.3.1. Key Market Trends and Opportunities
8.3.2. Market Size and Forecast, By Product Type
8.3.3. Market Size and Forecast, By Disease Type
8.3.4. Market Size and Forecast, By Test Type
8.3.5. Market Size and Forecast, By End User
8.3.6. Market Size and Forecast, By Country
8.3.7. Germany Autoimmune Disease Testing Market
8.3.7.1. Market Size and Forecast, By Product Type
8.3.7.2. Market Size and Forecast, By Disease Type
8.3.7.3. Market Size and Forecast, By Test Type
8.3.7.4. Market Size and Forecast, By End User
8.3.8. France Autoimmune Disease Testing Market
8.3.8.1. Market Size and Forecast, By Product Type
8.3.8.2. Market Size and Forecast, By Disease Type
8.3.8.3. Market Size and Forecast, By Test Type
8.3.8.4. Market Size and Forecast, By End User
8.3.9. UK Autoimmune Disease Testing Market
8.3.9.1. Market Size and Forecast, By Product Type
8.3.9.2. Market Size and Forecast, By Disease Type
8.3.9.3. Market Size and Forecast, By Test Type
8.3.9.4. Market Size and Forecast, By End User
8.3.10. Italy Autoimmune Disease Testing Market
8.3.10.1. Market Size and Forecast, By Product Type
8.3.10.2. Market Size and Forecast, By Disease Type
8.3.10.3. Market Size and Forecast, By Test Type
8.3.10.4. Market Size and Forecast, By End User
8.3.11. Spain Autoimmune Disease Testing Market
8.3.11.1. Market Size and Forecast, By Product Type
8.3.11.2. Market Size and Forecast, By Disease Type
8.3.11.3. Market Size and Forecast, By Test Type
8.3.11.4. Market Size and Forecast, By End User
8.3.12. Rest of Europe Autoimmune Disease Testing Market
8.3.12.1. Market Size and Forecast, By Product Type
8.3.12.2. Market Size and Forecast, By Disease Type
8.3.12.3. Market Size and Forecast, By Test Type
8.3.12.4. Market Size and Forecast, By End User
8.4. Asia-Pacific
8.4.1. Key Market Trends and Opportunities
8.4.2. Market Size and Forecast, By Product Type
8.4.3. Market Size and Forecast, By Disease Type
8.4.4. Market Size and Forecast, By Test Type
8.4.5. Market Size and Forecast, By End User
8.4.6. Market Size and Forecast, By Country
8.4.7. Japan Autoimmune Disease Testing Market
8.4.7.1. Market Size and Forecast, By Product Type
8.4.7.2. Market Size and Forecast, By Disease Type
8.4.7.3. Market Size and Forecast, By Test Type
8.4.7.4. Market Size and Forecast, By End User
8.4.8. China Autoimmune Disease Testing Market
8.4.8.1. Market Size and Forecast, By Product Type
8.4.8.2. Market Size and Forecast, By Disease Type
8.4.8.3. Market Size and Forecast, By Test Type
8.4.8.4. Market Size and Forecast, By End User
8.4.9. India Autoimmune Disease Testing Market
8.4.9.1. Market Size and Forecast, By Product Type
8.4.9.2. Market Size and Forecast, By Disease Type
8.4.9.3. Market Size and Forecast, By Test Type
8.4.9.4. Market Size and Forecast, By End User
8.4.10. Australia Autoimmune Disease Testing Market
8.4.10.1. Market Size and Forecast, By Product Type
8.4.10.2. Market Size and Forecast, By Disease Type
8.4.10.3. Market Size and Forecast, By Test Type
8.4.10.4. Market Size and Forecast, By End User
8.4.11. South Korea Autoimmune Disease Testing Market
8.4.11.1. Market Size and Forecast, By Product Type
8.4.11.2. Market Size and Forecast, By Disease Type
8.4.11.3. Market Size and Forecast, By Test Type
8.4.11.4. Market Size and Forecast, By End User
8.4.12. Rest of Asia-Pacific Autoimmune Disease Testing Market
8.4.12.1. Market Size and Forecast, By Product Type
8.4.12.2. Market Size and Forecast, By Disease Type
8.4.12.3. Market Size and Forecast, By Test Type
8.4.12.4. Market Size and Forecast, By End User
8.5. LAMEA
8.5.1. Key Market Trends and Opportunities
8.5.2. Market Size and Forecast, By Product Type
8.5.3. Market Size and Forecast, By Disease Type
8.5.4. Market Size and Forecast, By Test Type
8.5.5. Market Size and Forecast, By End User
8.5.6. Market Size and Forecast, By Country
8.5.7. Brazil Autoimmune Disease Testing Market
8.5.7.1. Market Size and Forecast, By Product Type
8.5.7.2. Market Size and Forecast, By Disease Type
8.5.7.3. Market Size and Forecast, By Test Type
8.5.7.4. Market Size and Forecast, By End User
8.5.8. Saudi Arabia Autoimmune Disease Testing Market
8.5.8.1. Market Size and Forecast, By Product Type
8.5.8.2. Market Size and Forecast, By Disease Type
8.5.8.3. Market Size and Forecast, By Test Type
8.5.8.4. Market Size and Forecast, By End User
8.5.9. South Africa Autoimmune Disease Testing Market
8.5.9.1. Market Size and Forecast, By Product Type
8.5.9.2. Market Size and Forecast, By Disease Type
8.5.9.3. Market Size and Forecast, By Test Type
8.5.9.4. Market Size and Forecast, By End User
8.5.10. Rest of LAMEA Autoimmune Disease Testing Market
8.5.10.1. Market Size and Forecast, By Product Type
8.5.10.2. Market Size and Forecast, By Disease Type
8.5.10.3. Market Size and Forecast, By Test Type
8.5.10.4. Market Size and Forecast, By End User
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top Winning Strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top Player Positioning, 2023
CHAPTER 10: COMPANY PROFILES
10.1. F. Hoffmann-La Roche Ltd
10.1.1. Company Overview
10.1.2. Key Executives
10.1.3. Company Snapshot
10.1.4. Operating Business Segments
10.1.5. Product Portfolio
10.1.6. Business Performance
10.1.7. Key Strategic Moves and Developments
10.2. Siemens
10.2.1. Company Overview
10.2.2. Key Executives
10.2.3. Company Snapshot
10.2.4. Operating Business Segments
10.2.5. Product Portfolio
10.2.6. Business Performance
10.2.7. Key Strategic Moves and Developments
10.3. Thermo Fisher Scientific Inc.
10.3.1. Company Overview
10.3.2. Key Executives
10.3.3. Company Snapshot
10.3.4. Operating Business Segments
10.3.5. Product Portfolio
10.3.6. Business Performance
10.3.7. Key Strategic Moves and Developments
10.4. Quest Diagnostics
10.4.1. Company Overview
10.4.2. Key Executives
10.4.3. Company Snapshot
10.4.4. Operating Business Segments
10.4.5. Product Portfolio
10.4.6. Business Performance
10.4.7. Key Strategic Moves and Developments
10.5. Abbott
10.5.1. Company Overview
10.5.2. Key Executives
10.5.3. Company Snapshot
10.5.4. Operating Business Segments
10.5.5. Product Portfolio
10.5.6. Business Performance
10.5.7. Key Strategic Moves and Developments
10.6. Werfen, S.A.
10.6.1. Company Overview
10.6.2. Key Executives
10.6.3. Company Snapshot
10.6.4. Operating Business Segments
10.6.5. Product Portfolio
10.6.6. Business Performance
10.6.7. Key Strategic Moves and Developments
10.7. Trinity Biotech
10.7.1. Company Overview
10.7.2. Key Executives
10.7.3. Company Snapshot
10.7.4. Operating Business Segments
10.7.5. Product Portfolio
10.7.6. Business Performance
10.7.7. Key Strategic Moves and Developments
10.8. Bio-Rad Laboratories, Inc.
10.8.1. Company Overview
10.8.2. Key Executives
10.8.3. Company Snapshot
10.8.4. Operating Business Segments
10.8.5. Product Portfolio
10.8.6. Business Performance
10.8.7. Key Strategic Moves and Developments
10.9. Grifols, S.A.
10.9.1. Company Overview
10.9.2. Key Executives
10.9.3. Company Snapshot
10.9.4. Operating Business Segments
10.9.5. Product Portfolio
10.9.6. Business Performance
10.9.7. Key Strategic Moves and Developments
10.10. Exagen Inc.
10.10.1. Company Overview
10.10.2. Key Executives
10.10.3. Company Snapshot
10.10.4. Operating Business Segments
10.10.5. Product Portfolio
10.10.6. Business Performance
10.10.7. Key Strategic Moves and Developments
